AzTrials
AzTrials

Parkinson DiseaseAPPROACHNCT07824128

Adaptango Performance PRocess for Older Adults Community reHabilitation

A study testing Adaptango Performance Process (APP) program in people with Parkinson Disease and Mild Cognitive Impairment, run by Emory University at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is being done to answer the question: How do people with Parkinson's disease, people with Mild Cognitive Impairment, and younger people process difficult topics in conversation? It will also explore themes related to dance, such as community building and justice, as perceived by persons with Parkinson's… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Adaptango Performance Process (APP) program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteUnited States
Study dates
Oct 2026to Sep 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Individuals (PWP, younger adults, PLwD) from the greater Atlanta area. Those in the PWP group must be diagnosed by a neurologist specialized in Parkinson's disease.
  • Score of at least 18 on the Montreal Cognitive Assessment (MoCA). Those who are in the PLwD group must score between 18 and 25 on the MoCA.

Who cannot join

  • Acute medical illness requiring hospitalization
  • Uncontrolled congestive heart failure
  • History of stroke in the past three years
  • Inability to perform study procedures
  • Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity)
  • Taking medications that could adversely affect cognition, e.g., antipsychotics, opioids, stimulants, chemotherapy, neurologic prescriptions to treat Multiple sclerosis. When applicable, enrollment will be delayed until dosages are stable on, e.g., Aricept, Namenda, anticholinesterase inhibitors, for at least 3 months
Show all 12Show fewer
  • Psychotic disorders
  • Confounding neurologic conditions [e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness >30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae]
  • Substance Use Disorder, Major Depressive Disorder, and Generalized Anxiety Disorders within six months of evaluation
  • Unable to provide informed consent
  • Cognitively impaired individuals or individuals with impaired decision-making, individuals who are not yet adults, pregnant women, prisoners
  • Not able to clearly understand English

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Madeleine E. Hackney, PhD contact

314-412-4852

mehackn@emory.edu

United States1 site
  • Emory University, Executive Park, Wesley Woods

    Atlanta, Georgia, 30329

Other trials in United States

About this study

Official title: Community-based Participatory Evaluation Studies on a Partnered Dance Program for Adults With Neurodegenerative Disease

This study is being done to answer the question: How do people with Parkinson's disease, people with Mild Cognitive Impairment, and younger people process difficult topics in conversation? It will also explore themes related to dance, such as community building and justice, as perceived by persons with Parkinson's disease or Mild Cognitive Impairment, and younger individuals before and after the Adaptango performance process.

Read the detailed description

This is a pilot study designed to assess the impact of the mediator/instructor role between dyads of older and younger adults as they engage in art and dance activities that address challenging topics.

The study aims to evaluate the effects of the Adaptango Performance Process (APP) on creativity, justice, and quality of life among persons with Parkinson's disease (PWP), people living with dementia (PLWD), and young adult participants. Validated measures of creativity, justice, and quality of life will be administered before and after the intervention.

The findings from this pilot phase will be used to inform the design and power calculations of future larger clinical trials intended to more definitively evaluate the effects of the APP program on creativity, engagement with challenging topics of societal importance, and psychosocial health across generations.

Findings from the arts-based method evaluation will also be considered when interpreting and reporting study results.

Being tested
Adaptango Performance Process (APP) program
Keywords
Dance, Music, Rehabilitation, Parkinson's, Motor-cognitive integration
Medical subject headings
Parkinson Disease, Cognitive Dysfunction, Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Adaptango Performance Process (APP) programOther

    Participants will take a three-month, biweekly choreographic process, ending in a weekend performance workshop at Emory University.

    Tango instructors undergo 13 hours of American Council on Exercise-certified training on Adaptango methods, age-specific functional impairments, and fall detection and prevention. Adaptango modifications were made to the frame and several steps of Argentine tango.

Study groups in NCT07824128
Study groupRoleWhat they receive
Healthy adults over 18 and less than 31 yearsExperimentalHealthy adults over 18 and less than 31 years
Receives: Other: Adaptango Performance Process (APP) program
Adults with Parkinson's disease (PD) age 50 years and overExperimentalAdults with Parkinson's disease aged 50 years and over
Receives: Other: Adaptango Performance Process (APP) program
Adults with mild cognitive impairment (MCI) age 50 years and overExperimentalAdults with MCI aged 50 years and over
Receives: Other: Adaptango Performance Process (APP) program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Participants' Satisfaction of the intervention (Acceptability)

    Satisfaction will be assessed post-intervention only with an Exit Questionnaire balanced for gender and race. Participants will rate (extremely easy/very easy) and their overall satisfaction with the intervention. A higher score indicates better satisfaction.

    Measured: Post-intervention at 8 months

  2. Alternate Uses Task (AUT)

    The Alternate Uses Task (AUT) will be used to assess the patient's creativity by asking them to come up with as many alternate uses for an everyday object as possible in two minutes. Results are measured across four subscales: fluency- the number of alternative uses thought of originality - how unusual the uses given are; flexibility - the range of ideas in different categories; and elaboration-the level of detail given to an idea. Higher values in each subscale indicate higher levels of creativity.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

Secondary outcomes (14)
  1. Parkinson's Disease Questionnaire Summary Index (PDQ-39 SI)

    The PDQ-39 is a patient-reported, disease-specific questionnaire used to assess health status and quality of life in Parkinson's disease over the preceding month. It consists of 39 items grouped into 8 distinct dimensions: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items), and bodily discomfort (3 items). Each item is scored on a 5-point Likert scale indicating frequency: 0 (never), 1 (occasionally), 2 (sometimes), 3 (often), and 4 (always or cannot do at all).

    The PDQ-39 Summary Index (PDQ-39 SI) is derived by calculating the mean of the 8 dimension scores.

    Total index scores range from 0 to 100. Lower scores reflect a better health status/quality of life, while higher scores indicate a greater frequency and severity of health-related difficulties.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  2. The Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    The Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a comprehensive 50-question clinical tool used to evaluate both motor and non-motor symptoms, severity, and progression of Parkinson's disease. Each item is scored from 0 (normal) to 4 (severe), with higher summed subscale scores indicating greater disability.

    Will you be reporting a paticular part of the scale, or are you reporting all? If so, we will need to entere separate parts with their respective scorings

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  3. 30-second chair stand test

    The number of sit-to-stand maneuvers completed in 30 seconds is used to measure leg strength and endurance. A higher score is better.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  4. Timed Up and Go Simple and Dual tasks (TUG, TUG Cognitive and TUG Manual)

    Measures the time it takes to rise from a chair, walk 3 meters, turn around, and return to the chair in the simple condition. In the Cognitive condition, one is required to simultaneously count backward by 3s from a number between 20 and 100; in the Manual condition, one is required to simultaneously pick up a cup of water and carry it while completing the task. A lower score is a better outcome.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  5. 360 turn test (Time)

    The time it takes the participants to turn around in a complete circle. Lower times are better.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  6. 360 turn test (steps)

    The number of steps the participant takes to turn around in a complete circle. Lower number of steps is better.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  7. Static Postural Balance Assessment via Tandem Stance Test

    Participants are instructed to stand with one foot directly in front of the other, heel-to-toe, with eyes open and arms at their sides or crossed over the chest. The examiner assists the participant into position and begins timing with a stopwatch once the examiner releases their hand support. Timing is recorded in seconds and ceases if the participant moves their feet, reaches for support, opens their eyes (if an eyes-closed variant), or reaches the ceiling threshold

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  8. Mini-Balance Evaluation Systems Test (Mini-BESTest)

    Mini-BESTest (Mini-Balance Evaluation Systems Test) is a validated, performance-based assessment used to evaluate balance, functional mobility, and fall risk. It includes 14 items across four domains, with each item scored from 0 to 2:

    2 = Normal: Completes the task safely, quickly, and independently.

    1 = Mild impairment: Completes the task with hesitation, slower movement, uneven weight shifts, or use of an assistive device.

    0 = Severe impairment/Unable: Requires physical assistance or cannot complete the task safely.

    Total Score Interpretation (0-28):

    27-28: Normal balance; no significant deficits. 22-26: Mild balance impairment; monitoring or preventive exercise may be beneficial.

    <22: Significant balance impairment, indicating increased balance dysfunction and fall risk.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  9. The Dynamic Gait Index (DGI)

    DGI is an 8-item clinical assessment used to evaluate gait adaptability and balance during functional walking tasks. Each item is scored on a 4-point scale (0-3): 3 = normal performance; 2 = mild impairment; 1 = moderate impairment; 0 = severe impairment or inability to perform independently.

    Total scores range from 0 to 24, with higher scores indicating better dynamic balance and mobility.

    Scores of 22-24 indicate normal balance and safe ambulation; 19-21 indicate mild instability; scores <19 are associated with increased fall risk in older adults and individuals with neurological conditions.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  10. Gait speed test

    Gait speed testing (Forward/Backwards/Fast): How quickly a person can walk a specific distance forward and Backwards using a stopwatch. Faster speeds (m/s) are better.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  11. Four-square step test

    The Four Square Step Test (FSST) is a quick clinical tool used to measure dynamic balance, agility, and the risk of falls by having a person rapidly step over low obstacles-traditionally four canes arranged in a plus-sign configuration on the floor. Because the Four Square Step Test (FSST) is a timed test, it does not use a point-based scale. Instead, performance is measured solely by the number of seconds it takes to complete the pattern. Normal values for the Four Square Step Test (FSST) generally range from under 10 to 15 seconds for healthy adults. A completion time of under 15 seconds indicates a low risk for falls in older adults, while a time of 15 seconds or longer suggests an increased risk for multiple falls.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

  12. The Multidimensional Scale of Perceived Social Support (MSPSS) Score

    The MSPSS has 12 items that assess how social support factors are perceived by individuals. This scale has three subscales to evaluate support by family, friends, and significant others. Respondents rate statements on a scale of 1 (very strongly disagree) to 7 (very strongly agree).

    Total scores range from 12 to 84, with higher scores being better and indicating an increased perception of social support.

    Measured: Baseline, 3 months (during APP ), and 8 months (after the APP program)

  13. The Short Form 12-Quality of Life (SF12)

    The SF12 evaluates the level of activity and perceived physical and mental quality of life. The SF-12 uses a standardized system with scores ranging from 0 to 100, where the general population's average is 50, with higher scores indicating better health. Because it measures relative deviation, the numbers represent the following health levels:

    Above 50: Better than average health. Exactly 50: Average health status. 40 to 50: Below average health (mild disability or impairment). 30 to 40: Moderate disability or impairment. Below 40: Severe impairment or disability.

    Measured: Baseline, 3 months (during APP ), and 8 months (after the APP program)

  14. The Impact on Participation and Autonomy Questionnaire (IPAQ).

    The Impact on Participation and Autonomy (IPA) instrument will be used to assess the patient's self-perceived freedom and social involvement. Individual items are graded on a 0-4 scale. Subscale scores will be calculated for Autonomy Indoors (0-28), Autonomy Outdoors (0-20), Family Role (0-28), Social Relations (0-28), and Work/Education (0-24). Higher subscale totals directly reflect an increase in perceived limitations and restrictions of participation. A reduction in subscale values indicates a positive clinical response to treatment.

    Measured: Baseline, 3 months (during intervention), and 8 months (post-intervention)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionSep 2029 (estimated)
  4. Study completionSep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07824128
Sponsor's protocol ID
2025P008930
Other IDs
1925601-38-24
Acronym
APPROACH
Status last verified
Sep 2026
First submitted
11 Sep 2026
Last updated
17 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Adaptango Performance Process (APP) program in people with Parkinson Disease and Mild Cognitive Impairment, run by Emory University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Madeleine E. Hackney, PhD (314-412-4852, mehackn@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Participants' Satisfaction of the intervention (Acceptability) (time frame: Post-intervention at 8 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in